All In Biotech

Drug Trial Radar · NCT02194738

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7,458

Actual

Start

Sep 26, 2014

Primary completion

Dec 3, 2025

Study completion Sep 21, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 18, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Conditions

  • Stage IB Lung Non-Small Cell Carcinoma AJCC v7
  • Stage II Lung Non-Small Cell Cancer AJCC v7
  • Stage IIA Lung Cancer AJCC v8
  • Stage IIB Lung Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIB Lung Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • CarboplatinDrug

    Given IV

  • CisplatinDrug

    Given IV

  • Clinical ObservationOther

    Undergo observation

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • CrizotinibDrug

    Given PO

  • Cytology Specimen Collection ProcedureOther

    Undergo collection of blood and tissue

  • Echocardiography TestProcedure

    Undergo ECHO

  • ErlotinibDrug

    Given PO

  • Gemcitabine HydrochlorideDrug

    Given IV

  • NivolumabBiological

    Given IV

  • PaclitaxelDrug

    Given IV

  • PembrolizumabBiological

    Given IV

  • PemetrexedDrug

    Given IV

  • Pemetrexed DisodiumDrug

    Given IV

  • Placebo AdministrationOther

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Central and local clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105Time frame: Up to 4 years
  2. Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysisTime frame: Up to 4 years

Locations

1,660 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Southern Cancer Center PC-Daphne

    Daphne, Alabama

  • Southern Cancer Center PC-Mobile

    Mobile, Alabama

  • Southern Cancer Center PC-Providence

    Mobile, Alabama

  • Southern Cancer Center PC-Springhill

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Banner-University Medical Center Phoenix

    Phoenix, Arizona

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner Boswell Medical Center

    Sun City, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Keck Medicine of USC Buena Park

    Buena Park, California

Showing 40 of 1,660 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.